Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Savient Pharmaceuticals, Inc. recently entered into an agreement with Swedish Company Sobi for the co-promotion of Kineret (anakinra) in the US. 

Kineret is approved for the reduction in signs and symptoms along with slowing the progression of structural damage in patients (18 years of age or older) suffering from moderately-to-severely active rheumatoid arthritis.

The patients have failed one or more disease modifying antirheumatic drugs (DMARDs).

The label of Kineret was expanded in Jan 2013 when the US Food and Drug Administration (FDA) approved the drug for the treatment of children and adults suffering from neonatal-onset multisystem inflammatory disease (NOMID). NOMID is a severe form of Cryopyrin-Associated Periodic Syndromes (CAPS).

The agreement provides Savient the exclusive right to co-promote Kineret with Sobi in the US.  Savient will market and promote Kineret from Apr 1, 2013.

Savient believes that Kineret complements the key focus of the company as it works to build upon its existing relationships with rheumatologists and patients while marketing its lead product, Krystexxa.

Krystexxa is approved in the US for the treatment of refractory chronic gout.  Meanwhile, Savient also received marketing authorization for Krystexxa from the EC. 

Savient gained approval from the EC for the treatment of severe debilitating chronic tophaceous gout in adults with erosive joint involvement.

These patients failed to normalize serum uric acid with xanthine oxidase inhibitors at the highest dose.

Currently, Savient Pharmaceuticals carries a Zacks Rank #3 (Hold). Pharma stocks that look better-placed include Array Biopharma (ARRY - Snapshot Report), Agenus Inc (AGEN - Snapshot Report) and Alkermes (ALKS - Analyst Report), all three carrying a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%